medigraphic.com
ISSN 1561-2945 (Print)

2022, Number 4

<< Back Next >>

Revista Cubana de Cirugía 2022; 61 (4)

Rejuvenation surgery with high-superficial musculoaponeurotic system flap

Valón CO, Romaguera BD, Rodríguez FZ, Romero GLI, Lubín GA

Language: Spanish
References: 15
Page:
PDF size: 467.42 Kb.


ABSTRACT

Introduction: Facial rhytidectomy is the technique for correcting facial aging features, but they are becoming increasingly complex due to the incorporation of deeper planes in the process. The superficial musculoaponeurotic system techniques have the advantage of providing a greater degree of naturalness and permanence in time.
Objective: To evaluate the effectiveness of the high-superficial musculoaponeurotic system technique for facial rejuvenation.
Methods: A prospective and longitudinal case series study was carried out in the plastic surgery service of Hospital General Universitario “Vladimir Ilich Lenin” with patients who requested facial rejuvenation and were treated with the high-superficial musculoaponeurotic system technique, from January 1, 2018 to June 30, 2020. The variables age, sex, skin type, degree of aging, operative complications, patient satisfaction and aesthetic outcomes were studied.
Results: The female sex predominated, together with the age group 50-59 years, the degrees of aging II and III, as well as white and light brown skin colors, while the most frequent operative complication was wound dehiscence of the suture line at the auricle root. The patients' satisfaction with the aesthetic outcomes of the surgical intervention was verified and the aesthetic outcomes was assessed as favorable in 100 % of the cases for the used surgical technique.
Conclusions: The high-superficial musculoaponeurotic system surgical technique for rhytidectomy offers harmonic, long-lasting outcomes with a low percentage of complications, making it a valuable alternative for patients.


REFERENCES

  1. Merlo IG, Fratantoni E, de Santibañes M, Ardiles V, Sánchez Clariá R, Pekolj J, et al1. . Supervivencia a largo plazo luego de pancreatectomía por cáncer de páncreas. Buenos Aires: Medicina. 2021[acceso 20/06/2022];81(5):800-7. Disponible en: Disponible en: http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-76802021000500800&lng=es 1.

  2. Zelaya Rodríguez GE. Morbimortalidad perioperatoria y principales complicaciones de los pacientes operados de Cirugía de Whipple por Cáncer de Páncreas y Neoplasias Periampulares. [Tesis en opción al título de Especialista en Cirugía General]. Managua: Universidad Nacional Autónoma de Nicaragua; 2021 [acceso 20/06/2022]. Disponible en: https://repositorio.unan.edu.ni/17121/1/17121.pdf2.

  3. Pasqua AV, Mazza OM. Adenocarcinoma ductal de páncreas. Soplan vientos de cambio. Acta Gastroenterol Latinoam. 2022;52(1):15-17. DOI:https://doi.org/10.52787/agl.v52i1.1633.

  4. Kohan G, Moro M, Pasqua A, Volpacchio M, Marcaccio F, Kujaruk M. Recomendaciones para el diagnóstico y tratamiento del Adenocarcinoma Ductal de Páncreas. Club del Páncreas de la República Argentina. Acta Gastroenterol Latinoam. 2020[acceso 20/06/2022];50(S2). Disponible en: Disponible en: https://www.redalyc.org/journal/1993/199368570001/199368570001.pdf 4.

  5. Madrigal Ureña A, García Chaves D. Cáncer de páncreas: alteraciones genéticas, cambios morfológicos y sus implicaciones terapéuticas. Med. Leg. Costa Rica. 2018[acceso 22/06/2022];35(1):3-10. Disponible en: Disponible en: http://www.scielo.sa.cr/scielo.php?script=sci_arttext&pid=S1409-00152018000100003&lng=en 5.

  6. Goggins M, Alexander Overbeek K, Brand R, Syngal S, Del Chiaro M, Bartsch D, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut. 2020;69(1):7-17. DOI:https://doi.org/doi:10.1136/gutjnl-2019-3193526.

  7. Pasqua A, Moro M, Alle L, Basso S, Canicoba M, Capitanich P, et al. Recomendaciones para el diagnóstico y tratamiento del adenocarcinoma ductal de páncreas. Acta Gastroenterol Latinoam. 2020;50(s2). DOI:https://doi.org/10.52787/XAQM86907.

  8. Alarcón Hermoza AM. Cáncer de páncreas, un enemigo de acción silente y rápida, y una limitación para la esperanza de vida. Rev. Méd. Urug. 2021[acceso 20/06/2022];37(1):e37115. Disponible en: Disponible en: http://www.scielo.edu.uy/pdf/rmu/v37n1/1688-0390-rmu-37-01-e801.pdf 8.

  9. McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS, et al. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018;24(43):4846-61. DOI:https://doi.org/10.3748/wjg.v24.i43.48469.

  10. Sung H, Ferlay J, Siegel RL. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. DOI:https://doi.org/10.3322/caac.2166010.

  11. Romaguera Barroso D, Kénol S, León Goire WL, Cisneros Domínguez CM, Rodríguez Fernández Z, Rodríguez López H, et al11. . Caracterización de pacientes con neoplasias primarias del segmento hepatobiliopancreático. MEDISAN. 2015[acceso 22/06/2022];19(2):158-68. Disponible en: Disponible en: http://www.medisan.sld.cu/index.php/san/article/download/137/pdf_22 11.

  12. Medina Perez VM, Fonseca Labrada A, Alsina Tul LE, Lamadrid García J, Carvajal Aballe ML, Fong Baltar AL, et al12. . Caracterización de pacientes con adenocarcinoma de páncreas. Rev. Cubana de Oncología. 2020[acceso 08/06/2022];18(2):e_35. Disponible en: http://www.revoncologia.sld.cu/index.php/onc/article/view/3512.

  13. Merkow RP, Bilimoria KY, Tomlinson JS, Paruch JL, Fleming JB, Talamonti MS, et al. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg. 2014;260(2):372-7. DOI:https://doi.org/10.1097/SLA.000000000000037813.

  14. Casciani F, Trudeau MT, Asbun HJ, Ball CG, Bassi C, Behrman SW, et al. Pancreas Fistula Study Group. The effect of high intraoperative blood loss on pancreatic fistula development after pancreatoduodenectomy: An international, multi-institutional propensity score matched analysis. Surgery. 2021;170(4):1195-204. DOI:https://doi.org/10.1016/j.surg.2021.03.04414.

  15. Sánchez Morales GE, Moguel Valladares RA, Flores Maza J, Clemente Gutiérrez U, Sánchez-García Ramos E, Domínguez Rosado I, et al15. . Pancreatic ductal adenocarcinoma: Eleven years of experience at a tertiary care hospital center. Rev. de Gastroenterología de México. 2021[acceso 28/06/2022];86:118-124. Disponible en: Disponible en: https://www.sciencedirect.com/science/article/pii/S0375090620300513 15.




2020     |     www.medigraphic.com